Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267381 · ClinicalTrials.gov registry record
Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 37
- Enrollment target
NCT03267381: Completed study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT03267381 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03267381 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
To study if a targeted gene expression profile of RNA, similar to the NETest, can be isolated from the peripheral blood of patients with melanoma, to identify active disease, provide an assessment of treatment responses, or predict risk of relapse, in conjunction with standard clinical assessment and imaging.
Primary Outcome
Evaluate the diagnostic efficacy of a circulating melanoma gene signature in pathologically verified Stage III melanoma at diagnosis (biopsy-proven lymph node positive) and compare this to LDH as a biomarker.
Interventions
- OTHER Blood draw (before surgery)
- OTHER Blood draw (every 3 months)
- OTHER Blood draw (at diagnosis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2023-09-27 |
What the finished NCT03267381 record still lists
NCT03267381 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Blood draw (before surgery) is the first listed.
NCT03267381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03267381 about?
NCT03267381 is a clinical study titled "Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy". To study if a targeted gene expression profile of RNA, similar to the NETest, can be isolated from the peripheral blood of patients with melanoma, to identify active disease, provide an assessment of treatment responses, or predict risk of relapse, in conjunction with standard clinical assessment an...
What is the current status of trial NCT03267381?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2017-10-03. Estimated completion is 2023-09-27.
What interventions are being tested in trial NCT03267381?
The interventions under investigation include: Blood draw (before surgery) (OTHER), Blood draw (every 3 months) (OTHER), Blood draw (at diagnosis) (OTHER).
Who is sponsoring clinical trial NCT03267381?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI